CD44 and endometrial cancer: The ofCS-CD44 showed the highest AUC in the biomarker discovery set (AUC = 0.84) and validation cohort 1 (AUC = 0.83), which achieved a better performance than a recent single biomarker study in colorectal cancer (AUC of 0.62)62 and in endometrial cancer (AUC of 0.799)63.